Nachrichten zur Moderna Inc. Aktie

Moderna: Speculative Buy For Aggressive Investors Betting On mRNAs Future

Modernas mRNA pipeline—cancer vaccines, Norovirus, and a European comeback—could fuel triple-digit EPS growth by 2030. Read why MRNA stock is…

Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100%…

Moderna (MRNA) Stock Dips While Market Gains: Key Facts

In the closing of the recent trading day, Moderna (MRNA) stood at $49.2, denoting a -1.66% move from the preceding…

Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.…

Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up…

Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know…

Moderna (MRNA) Falls More Steeply Than Broader Market: What Investors Need to Know

Moderna (MRNA) concluded the recent trading session at $49.56, signifying a -7.49% move from its prior days close.…

These Top Stocks Have a Big China Problem to Solve

Modern problems require modern solutions, and thats what Detroit automakers are currently figuring out in China.…

ImmunityBio vs. Moderna: Which Biotech Has More Upside Potential?

IBRX and MRNA hinge on single-drug success, but pipeline depth, growth plans and risks set them apart in the race…

Moderna Stock is Soaring. Is It Too Late to Buy?

Modernas full pipeline may fuel long-term growth.…

Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights

In the latest trading session, Moderna (MRNA) closed at $51.38, marking a -1.89% move from the previous day.…

Pfizer vs Moderna: Which Pharma Stock Has More Upside?

They arent just "pandemic stocks."…

OTC Markets Hosts Virtual Investor Presentation with Dr. Seth Lederman, Co-Founder, CEO, and Chairman of Tonix Pharmaceuticals, and David Bautz, PhD, Senior Analyst at Zacks SCR

NASDAQ: TNXPJohn Viglotti: Hello, and welcome to the Life Sciences Investor Forum. On behalf of OTC Markets and our co-host,…

Moderna (MRNA) Declines More Than Market: Some Information for Investors

In the most recent trading session, Moderna (MRNA) closed at $52.56, indicating a -1.55% shift from the previous trading day.…

Stocks making the biggest moves midday: Coinbase, CoreWeave, KKR, Moderna, Brown-Forman & more

Here are some of the stocks making the biggest moves in midday trading.…

Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang

Moderna shares rose 10% in premarket trading on Wednesday after the company settled a long-running legal battle over the technology…

Stocks making the biggest moves premarket: Moderna, Ross Stores, Box, Gitlab and more

These are the stocks posting the largest moves in premarket trading.…

Moderna to pay up to $2.25B to settle COVID vaccine patent matter

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) stock added almost 9% after it was announced that the drugmaker has agreed to pay up…

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

BASEL, Switzerland and VANCOUVER, British Columbia, March 03, 2026 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid…

Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna

BASEL, Switzerland and LONDON and NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced…

Grünes Licht für erste Kombi-Impfung gegen Covid und Grippe

AMSTERDAM (dpa-AFX) - Die EU-Arzneimittelbehörde EMA hat grünes Licht gegeben für den ersten Kombi-Impfstoff gegen Corona…

Pivotal-Point Nachverfolgung Moderna (MRNA): Abkehr vom COVID-Fokus nach Durchbruch bei personalisierter Krebs-Immuntherapie!

Moderna ist ein Pionier im Bereich der mRNA-Technologie und wurde durch den Erfolg seines COVID-19-Vakzins weltweit bekannt. Am 18. Februar…

Modernas Ups and Downs: Heres What You Need to Know Before Investing.

The stock, after a few tough years, soared in the double-digits in January.…

Moderna Aktie: Paukenschlag - aber kein Grund zur Euphorie!

Charlotte (www.aktiencheck.de) - Moderna-Aktienanalyse der Bank of America (BofA):Der BofA-Analyst Alex Stranahan habe das Kursziel für die Aktie von Moderna…

Netflix, Klarna, Shopify, Palo Alto, Moderna: What brokers said this week

…

BioNTech verklagt Moderna – die Details

BioNTech ist im Patentstreit gegen Moderna vor Gericht gezogen. Das Mainzer Biotech-Unternehmen hat beim Bundesgericht im US-Bundesstaat Delaware Klage eingereicht…

Moderna Aktie: FDA-Kehrtwende beim Grippeimpfstoff - Kommt die Zulassung noch 2026?

Toronto (www.aktiencheck.de) - Moderna-Aktienanalyse von RBC Capital Markets:Die Analysten von RBC Capital bewerten die Aktie von Moderna Inc. (ISIN: US60770K1079,…

How to Buy Moderna Stock (MRNA) in 2026

Moderna is a well-known biotech company from its pandemic success. Heres what investors should know about its growth story now.…

FDA agrees to review Moderna’s mRNA flu vaccine application in a reversal

The FDA is slated to make a decision on the flu shot on Aug. 5, which will allow Moderna to…

Moderna Shares Rally 6% After FDA Reverses Decision Not To Review Flu Vaccine

The agency previously told Moderna its application did not contain an “adequate and well-controlled” trial.…

Moderna Aktie: Trotz FDA-Dämpfer erstaunlich stabil

New York (www.aktiencheck.de) - Moderna-Aktienanalyse von Sanford C. Bernstein & Co:Bernstein habe das Kursziel für die Aktie von Moderna Inc.…

Moderna dealt blows in ongoing patent dispute with Arbutus

…

US FDA to initiate review of Modernas influenza vaccine

Moderna said on Wednesday the U.S. Food and Drug Administration has accepted its application to review its influenza vaccine candidate.…

Moderna’s investigational flu vaccine moves forward in FDA review

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) announced that the US Food and Drug Administration (FDA) will initiate review of its investigational seasonal…

Moderna Aktie: Showdown im März und Phase-3-Daten im Anflug!

New York (www.aktiencheck.de) - Moderna-Aktienanalyse von Morgan Stanley:Die Analysten von Morgan Stanley haben das Votum für die Aktie von Moderna…

Moderna erhöht Cash-Polster - Sinkende US-COVID-Erlöse

Charlotte (www.aktiencheck.de) - Moderna-Aktienanalyse von BofA Securities:Die Analysten von BofA Securities haben das Kursziel für Moderna Inc. (ISIN: US60770K1079, WKN:…

Moderna: Umsatz-Überraschung und Krebs-Pipeline – der Startschuss für die Neubewertung ist gefallen!

Moderna trotzt dem Abgesang auf die Post-Covid-Ära und übertrifft mit einem Umsatz von 678 Mio. USD im 4. Quartal die…

Notable healthcare headlines for the week: AstraZeneca, CVS Health, and Moderna in focus

…

Stocks making the biggest moves midday: Moderna, Instacart, Rivian Automotive, DraftKings, Coinbase & more

Here are some of the biggest movers in midday trading.…

Moderna Q4 Loss Narrower-Than-Expected, Sales Beat Estimates

MRNA posts a narrower Q4 loss and beats sales estimates, despite a 30% revenue drop, while advancing its pipeline and…

ROUNDUP/Nach Umsatzeinbruch: Moderna will 2026 wieder wachsen

CAMBRIDGE (dpa-AFX) - Ungeachtet eines überraschend starken Schlussquartals hat der US-Pharmakonzern Moderna 2025 einen harschen…

Market movers: Moderna, Pinterest, DraftKings, Coinbase, Immunic...

…

Nach Umsatzeinbruch: Moderna will 2026 wieder wachsen

CAMBRIDGE (dpa-AFX) - Ungeachtet eines überraschend starken Schlussquartals hat der US-Pharmakonzern Moderna 2025 einen harschen…

Earnings Snapshot: Moderna tops Q4; sees up to 10% revenue growth, lower expenses in 2026

…

Moderna beats quarterly revenue estimates on resilient sales of COVID shot

Moderna reported fourth-quarter revenue above Wall Street estimates on Friday, banking on better-than-expected sales of its COVID-19 vaccine in the…

Moderna shares pop on strong guidance, smaller-than-expected loss

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) reported fourth quarter 2025 results that exceeded Wall Street expectations, sending its shares up about 11%…

HHS Casts Doubts On mRNA Products, But Funds Studies On Debunked Theories

Its conspicuous that HHS refuses to review Modernas application for regulatory approval of an mRNA-based flu vaccine while it prioritizes…

Moderna: Stock to Avoid or Bad News Buy?

Moderna stock was a highflier in early pandemic days as sales of its coronavirus vaccine soared.…

Moderna Aktie: Regulatorischer Dämpfer - Grippeimpfstoff mRNA-1010 im Fokus

Boston, MA (www.aktiencheck.de) - Moderna-Aktienanalyse von Leerink Partners:Die Analysten von Leerink Partners stufen die Aktie von Moderna Inc. (ISIN: US60770K1079,…

Moderna Aktie: FDA stoppt Grippeimpfstoff-Antrag, Break-even rutscht auf 2030

Charlotte (www.aktiencheck.de) - Moderna-Aktienanalyse der Bank of America (BofA):BofA habe das Kursziel für die Aktie von Moderna Inc. (ISIN: US60770K1079,…